Connect with us

Technology

Axtria is Revolutionizing Field Force Management for Life Sciences and Pharma Companies

Published

on

BERKELEY HEIGHTS, N.J., Sept. 24, 2024 /PRNewswire/ — Life Sciences and Pharma industry leaders are turning to Axtria for cutting-edge solutions that boost field force effectiveness. Axtria’s innovative approach integrates data, AI, GenAI, orchestration, and user experience into a unified platform, setting a new benchmark in the industry.

Our AI optimization can increase field productivity by more than 30%.

Empowering Field Teams with AI-Driven Solutions

Axtria’s unified commercial ecosystem personalizes interactions at scale and delivers superior customer outcomes. With actionable insights available at the point of decision, field teams can prioritize high-value opportunities and execute strategies with unmatched precision. Seamless integration across sales, marketing, and customer engagement aligns every part of commercial operations, streamlining processes and encouraging cross-functional collaboration to drive sustained growth.

“Our AI optimization can increase field productivity by more than 30%, freeing up to 40% of a rep’s time for face-to-face interactions,” said Asheesh Sharma, Head of Commercial Excellence at Axtria. “It’s essential to have a scalable and agile ecosystem that breaks silos across sales and marketing, adjusts quickly to new market needs, and personalizes experiences for healthcare providers.”

Proven Results

Over 100,000 field reps trust Axtria to help them move from insight to action. The company’s integrated platform is the industry’s go-to solution, combining the field user experience into one seamless system. Axtria provides field teams with actionable insights that enhance precision and efficiency, empowering them to speed up market entry, outpace competitors, and deliver superior results in a rapidly changing market landscape.

A Commitment to Innovation

Axtria’s end-to-end platform accelerates market penetration, enabling new brands to onboard efficiently and reducing the time to market by up to half. This ensures optimal territory alignment and market coverage, enhancing field teams’ capacity to deliver superior customer experiences and access the latest patient treatments.

“There’s a reason we’ve been working with Axtria for more than four years,” said Richard Ciorra, Vice President of Commercial Operations at SK Life Science. “Axtria successfully makes the lines between our teams invisible. We’re focused on the same goals and metrics and, at the end of the day, that’s a great thing to be a part of.”

Powered by GenAI

Axtria’s products harness the power of GenAI, providing field representatives with personalized, data-driven insights, pre-call planning, Customer 360 views, and help queries related to incentive compensation programs through a domain-augmented co-pilot experience. Our integrated experience brings together Next Best Action (NBA) recommendations that align with market dynamics.

“With the entrepreneurial spirit of a startup and drive for innovation, we work with the world’s top life sciences companies to harness the potential of data science, technology, and humanity for improved patient outcomes. We don’t just collaborate with our clients; we imagine, dare, and transform with them daily,” added Asheesh Sharma.

For more information or to schedule a demo, please get in touch with us here.

About Axtria’s Products and Solutions

Axtria is proud to work with 16 of the top 20 life sciences companies, globally. From our roots as a trusted consultant to our status as one of the world’s leading providers of cloud-based pharmaceutical management software, Axtria has been powering the digital transformation of life sciences. Our experts call upon years of domain experience in the industry to guide pharma giants from brand launches to retirement. Our products go even further. Axtria InsightsMAx™ helps everyone from the C-suite to junior associates uncover trends to make better decisions. Axtria SalesIQ™ helps optimize field forces and provider engagements. Axtria CustomerIQ™ leverages AI-enabled next-best-action omnichannel choices. Axtria MarketingIQ™ turns investment analyses into pinpoint strategies. And Axtria DataMAx™ and DataMAx™ for Emerging Pharma is the data management framework that pulls it all together with best-in-class security and integration.

About Axtria

Axtria helps life sciences companies harness the potential of data science and software to improve patient outcomes by connecting the right therapies to the right patients at the right time. The company is a leading global provider of award-winning cloud software and data analytics to the life sciences industry. We’re proud to deliver proven solutions that help pharmaceutical, medical device, and diagnostics companies complete their journey from data to insights to action, enabling them to earn superior returns on their investments. As a participant in the United Nations Global Compact, Axtria is committed to aligning strategies and operations with universal principles on human rights, labor, environment, and anti-corruption, and taking actions that advance societal goals. For more information, please visit www.axtria.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/axtria-is-revolutionizing-field-force-management-for-life-sciences-and-pharma-companies-302255777.html

SOURCE Axtria, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Quarterhill Awarded High-Speed Weigh-In-Motion Prescreening Contract in Belgium

Published

on

By

The new WIM station will assist Brussels Mobility in achieving its goals of improving road safety and creating a fair regulatory environment by reducing the number of overloaded vehicles on the roads of the Brussels region.Traffic data provided by the system will support Brussels Mobility’s mission to foster economic growth and improve quality of life through the development of transport infrastructure.

TORONTO, Jan. 10, 2025 /PRNewswire/ – Quarterhill Inc. (“Quarterhill” or the “Company”) (TSX: QTRH) (OTCQX: QTRHF), announced today a contract to provide weigh-in-motion (“WIM”) technology to Brussels Mobility through a joint project with Belgium-based technology integrator Jacops NV (“Jacops”). Quarterhill will be responsible for the design and supply of the WIM subsystem, technical support, and training. Quarterhill will also provide Jacops with the software necessary for commercial vehicle monitoring and enforcement.

Quarterhill will supply the WIM system for the Brussels-Capital Region weigh station, which will be used to pre-select overloaded vehicles for enforcement. The dynamic weighing station will promote and improve the efficiency of inspections by screening vehicles at highway speeds in advance of the law enforcement inspection site. In addition, the weigh station will generate data that provides an accurate, real-time picture of the vehicles on the E19 highway.

The system’s goal is to reduce the number of overloaded vehicles on the Brussels Region’s roads. Overloading causes many problems, such as rapid road deterioration, more serious accidents, and unfair competition between transport companies. Quarterhill’s technology mitigates these issues by screening for overweight vehicles while optimizing the use of enforcement resources.

“We are excited at the prospect of introducing our advanced enforcement technology to Brussels Mobility and expanding our presence in Europe,” said Chuck Myers, CEO of Quarterhill. “Together with Jacops, we will deploy a state-of-the-art high-speed WIM system that will make Belgian roads safer and more sustainable. We have a longstanding relationship with Jacops as a customer for our microwave sensor products, and this project demonstrates how having a broad portfolio of traffic technologies and established relationships with traffic system integrators leads to further opportunities.”

The weigh station will monitor four lanes of one-way traffic on the highway and record data on vehicle classification and vehicle tax without impeding traffic. An overview camera provides images to help enforcement personnel clearly identify vehicles flagged by the system. An Automated Number Plate Reader system will photograph, recognize, store, process, and transmit the number plates of vehicles approaching the dynamic weighing station.

Quarterhill’s iSINC WIM controller was selected for the project as it offers preselection of overweight vehicles, creates comprehensive vehicle records, classifies vehicles, and meets the desired standards for continual uptime monitoring and ease of service. iSINC’s versatility allows it to control a wide array of sensors, cameras, dimensioning systems, communication systems, and custom equipment.

WIM sensors that comply with the accuracies outlined in the Nmi International WIM standard Specification and test procedures for WIM Systems will be installed at the site. The WIM sensors meet the lane width specifications and provide high durability, stable output over time, and IP68 water resistance.

Quarterhill will advise Jacops on the design and placement of the WIM system components to ensure optimal operation, including onsite technical support for installation, testing, and initial calibration. Quarterhill will also provide Jacops with thorough training on the WIM components and system calibration. Over the 2-year warranty period, Quarterhill will provide remote diagnostics and technical support to ensure continuous uptime and optimal performance.

“This project shows that Quarterhill’s technology is well suited to the precise needs of European agencies. We are set to elevate road safety and integrity in the region, reinforcing our expanding footprint in this important market,” stated Heimo Haub, Managing Director, Quarterhill Europe.

About Quarterhill
Quarterhill is a leading provider of tolling and enforcement solutions in the Intelligent Transportation System (ITS) industry. Our goal is technology-driven global leadership in ITS, via organic growth of our tolling and enforcement businesses, and by continuing an acquisition-oriented investment strategy that capitalizes on attractive growth opportunities within ITS and its adjacent markets. Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF. For more information: www.quarterhill.com.

Forward-looking Information
This news release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Such forward-looking statements relate to future events, conditions or future financial performance of ‎Quarterhill based on future economic conditions and courses of action. All statements other ‎than statements of historical fact may be forward-looking statements. Such forward-looking statements ‎are often, but not always, identified by the use of any words such as “seek”, “anticipate”, “budget”, ‎‎”plan”, “goal”, “expect” and similar expressions.

Forward-looking statements involve known and unknown risks, assumptions, ‎uncertainties and other factors that may cause actual results or events to differ materially from those ‎anticipated in such forward-looking statements. Material risk factors that could cause actual results to differ materially from the forward-looking statements contained in this news release include, among others, demand for Quarterhill’s products and services; general economic and market conditions; competition; risks relating to technological advances and cyber-security; and other risks set forth in the Company’s most recent annual information form available on SEDAR+ at www.sedarplus.ca. The Company believes the expectations reflected in ‎the forward-looking statements are reasonable, but no assurance can be given that these expectations ‎will prove to be correct and such forward-looking statements included in this news release should not be ‎unduly relied upon.‎ Material factors and assumptions used to develop the forward-looking statements contained in this news release include, among others: Quarterhill’s ability to execute on its business plan; demand for Quarterhill’s products and services; operating assumptions; and financial projections and cost estimates. Quarterhill has no intention, and undertakes no obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View original content:https://www.prnewswire.com/news-releases/quarterhill-awarded-high-speed-weigh-in-motion-prescreening-contract-in-belgium-302347610.html

SOURCE Quarterhill

Continue Reading

Technology

ez1099 2024 Edition Tax Preparation Software for 2025 Tax Season Is Available for Electronic Filing

Published

on

By

REDMOND, Wash., Jan. 10, 2025 /PRNewswire/ — Designed for US business owners, tax professionals and entrepreneurs, the latest ez1099 tax form software from Halfpricesoft.com is easy to navigate and streamline processing unlimited forms for multiple companies for one flat rate.  The latest edition of ez1099 supports paper form printing, pdf printing and efile feature. It also comes with a recipient data import feature from the spreadsheet and QuickBooks IIF file.

 

“ez1099 2024 software is now available for business owners and tax professionals to print and file 1098’s and 1099’s, seamlessly.” Dr. Ge, Founder of Halfpricesoft.com, says.

ez1099 software streamlines the preparation, printing, and e-filing of essential IRS forms, including W2G, 1097BTC, various 1098 forms (1098, 1098C, 1098E, 1098F, 1098Q, 1098T), numerous 1099 forms (1099A, 1099B, 1099C, 1099CAP, 1099DIV, 1099G, 1099INT, 1099K, 1099LTC, 1099MISC, 1099NEC, 1099OID, 1099PATR, 1099Q, 1099QA, 1099R, 1099S, 1099SB, 1099SA), 5498 forms (5498, 5498ESA, 5498QA, 5498SA), as well as 8935, 3921, 3922, and 1096 forms.

Cost is only $79 per installation for the basic version of ez1099 Software or $139 per installation for the advanced version with bulk printing feature, import feature, PDF file creation and electronic filing capability. Also offered in a network version for two or more installations starting at $199 to enable sharing data between computers or offices.

ez1099 is compatible with Windows 11, 10, and 8.  It can also run on Windows Vista system, 7, and MAC machines (Mac can run the system only if installed with Bootcamp).

The features in the latest version ez1099 software include but are not limited to:

electronically file unlimited forms to the IRS with one flat rateez1099 blank paper prints out recipient copiesPrint in bulk for faster processingQuick data importing featureCustomers can save even more time by compiling and saving form data for later use and modificationSupport unlimited accounts and unlimited recipients at no additional chargeGo green with optional PDF document converting and e-file (electronic filing) featuresFeature to process correction forms included

Starting at $79.00 for the print and mail version and $139.00 to electronically file. Halfpricesoft.com welcomes all clients to begin the no obligation thirty-day test drive today at https://www.halfpricesoft.com/1099_software.asp#purchase

About halfpricesoft.com

Halfpricesoft.com is a leading provider of small to midsize business software, including online and desktop payroll software, online employee attendance tracking software, accounting software, in-house business and personal check printing software, W2, software, 1099 software, 1095 ACA form software and ezACH direct deposit software. Software from halfpricesoft.com is trusted by thousands of customers for over 20 years and will assist business owners simplify payroll processing and streamline business management.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ez1099-2024-edition-tax-preparation-software-for-2025-tax-season-is-available-for-electronic-filing-302340859.html

SOURCE Halfpricesoft.com

Continue Reading

Technology

The New York Stem Cell Foundation Research Institute Enters Agreement to Accelerate Precision Drug Discovery for Neurodegenerative Disease

Published

on

By

Partnership Will Harness NYSCF’s Automated Cell Culture Systems and Artificial Intelligence Capabilities to Study Disease at an Unprecedented Cellular Level

NEW YORK, Jan. 10, 2025 /PRNewswire/ — The New York Stem Cell Foundation (NYSCF) Research Institute today announced they have entered into an agreement with Janssen Research & Development, LLC, a Johnson & Johnson company, to use NYSCF’s AI-powered platform for drug discovery to target neurodegenerative disease. This initiative brings together NYSCF’s advanced robotic systems for stem cell research and J&J’s expertise in drug discovery and data science to unlock novel disease insights and accelerate the development of more effective and tailored treatments.

NYSCF has developed proprietary automation technology that enables large-scale, reproducible disease modeling and drug screening using patient-derived stem cells. By combining high-content cell imaging with machine learning-driven analysis, NYSCF’s platform can reveal previously undiscovered disease phenotypes and therapeutic targets leading to the development of novel therapeutic approaches. This versatile platform is adaptable to a wide range of cell types and diseases, making it uniquely positioned to advance precision medicine for patients.

“This work with Johnson & Johnson allows us to integrate our cutting-edge stem cell automation and AI platform with their deep expertise in therapeutic development,” said Jennifer J. Raab, President and CEO of NYSCF. “Together, we look forward to accelerating the discovery of innovative treatments for patients affected by devastating neurodegenerative disease.”

About The New York Stem Cell Foundation Research Institute
The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research. The NYSCF Research Institute is an acknowledged world leader in stem cell research and in the development of pioneering stem cell technologies, including the NYSCF Global Stem Cell Array®, which is used to create cell lines for laboratories around the globe. NYSCF focuses on translational research in an accelerator model designed to overcome barriers that slow discovery and replace silos with collaboration. For more information, visit nyscf.org.

CONTACTS:
David McKeon
212-365-7440
dmckeon@nyscf.org

Chris Taylor
chris@christaylorpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-new-york-stem-cell-foundation-research-institute-enters-agreement-to-accelerate-precision-drug-discovery-for-neurodegenerative-disease-302347569.html

SOURCE The New York Stem Cell Foundation

Continue Reading

Trending